|
Accueil > Actualité
AstraZeneca: promising trial in hypoparathyroidism
(CercleFinance.com) - AstraZeneca announces that a Phase III trial with eneboparatide (AZP-3601) in adults with chronic hypoparathyroidism has met its primary endpoint, showing normalization of blood calcium without the need for active vitamin D or oral calcium after 24 weeks.
This rare endocrine disease affects over 200,000 people in the United States and Europe. The safety of the treatment has been confirmed, and a full analysis of the 52-week data is awaited before submission to the health authorities. Copyright (c) 2025 CercleFinance.com. All rights reserved. |
18/03/2025 07:20
Peugeot Investallègement au capital de Spie 17/03/2025 19:55 Charwoodmodernisation du site breton de méthanisation 17/03/2025 17:09 SpieAmundi Asset Management sous les 10% des votes 17/03/2025 16:47 Bureau VeritasBlackRock détient plus de 5% du capital 17/03/2025 16:35 OrangeBlackRock sous les 5% du capital 17/03/2025 16:25 RWEétape importante pour le parc éolien offshore de Sofia Tous les articles sociétés |
